Monohon Ted
Known title: Chief Accounting Officer & VPCIK: 0001606905
Associated companies
Transaction History
| QNCX | ▼ Sell | Open Market | 1,871 | $2K | 3/6/2023 | View on chart |
| QNCX | ▼ Sell | Tax Withholding | 1,640 | $1K | 12/5/2022 | View on chart |
| QNCX | ▼ Sell | Tax Withholding | 1,520 | $2K | 9/6/2022 | View on chart |
| QNCX | ▼ Sell | Tax Withholding | 1,529 | $5K | 6/6/2022 | View on chart |
| QNCX | ▲ Buy | Grant | 34,000 | $0 | 3/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Quince Therapeutics LAM-001 Progress; Analyst Targets $70
Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.
Quince Therapeutics LAM-001 Progress; Analyst Targets $70. Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.